Shattuck Labs, Inc.
STTKHeld by 3 specialist biotech funds
High Convergence3 funds opened new positions. Next phase2 readout (SL-325): Jul 2028. Short interest: 1.6% of float.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.